Publications

Journal articles

  1. Sutherland, G.; Mellick, G.; Sue, C.; Chan, D. K.; Rowe, D.; Silburn, P.; Halliday, G. A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neurosci Lett 2007, 414, 170-3.
  2. Mo, Y. K.; Kankavi, O.; Masci, P. P.; Mellick, G. D.; Whitehouse, M. W.; Boyle, G. M.; Parsons, P. G.; Roberts, M. S.; Cross, S. E. Surfactant protein expression in human skin: evidence and implications. J Invest Dermatol 2007, 127, 381-6.
  3. Mellick, G. D. TNF gene polymorphism and quantitative traits related to cardiovascular disease: getting to the heart of the matter. Eur J Hum Genet 2007, 15, 609-11.
  4. Manathuga, C.; Lant, P.; Mellick, G. Developing professional independent researchers: research students' graduate attributes. Studies in Continuing Education 2007, 29, In Press.
  5. Huang, Y.; Halliday, G. M.; Vandebona, H.; Mellick, G. D.; Mastaglia, F.; Stevens, J.; Kwok, J.; Garlepp, M.; Silburn, P. A.; Horne, M. K.; Kotschet, K.; Venn, A.; Rowe, D. B.; Rubio, J. P.; Sue, C. M. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord 2007, 22, 982-9.
  6. Dissanayaka, N. N.; Sellbach, A.; Matheson, S.; Marsh, R.; Silburn, P. A.; O'Sullivan, J. D.; Byrne, G. J.; Mellick, G. D. Validity of Hamilton Depression Inventory in Parkinson's disease. Mov Disord 2007, 22, 399-403.
  7. Buchanan, D. D.; Silburn, P. A.; Prince, J. A.; Mellick, G. D. Association of APOE with Parkinson disease age-at-onset in women. Neurosci Lett 2007, 411, 185-8.
  8. Sellbach, A. N.; Boyle, R. S.; Silburn, P. A.; Mellick, G. D. Parkinson's disease and family history. Parkinsonism Relat Disord 2006, 12, 399-409.
  9. Peters, C. M.; Gartner, C. E.; Silburn, P. A.; Mellick, G. D. Prevalence of Parkinson's disease in metropolitan and rural Queensland: a general practice survey. J Clin Neurosci 2006, 13, 343-8.
  10. Motsinger, A. A.; Lee, S. L.; Mellick, G.; Ritchie, M. D. GPNN: power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease. BMC Bioinformatics 2006, 7, 39.
  11. Mellick, G. D.; Gartner, C. E.; Silburn, P. A.; Battistutta, D. Passive smoking and Parkinson disease. Neurology 2006, 67, 179-80.
  12. Mellick, G. D. CYP450, genetics and Parkinson's disease: gene x environment interactions hold the key. J Neural Transm Suppl 2006, 159-65.
  13. Maraganore, D. M.; de Andrade, M.; Elbaz, A.; Farrer, M. J.; Ioannidis, J. P.; Kruger, R.; Rocca, W. A.; Schneider, N. K.; Lesnick, T. G.; Lincoln, S. J.; Hulihan, M. M.; Aasly, J. O.; Ashizawa, T.; Chartier-Harlin, M. C.; Checkoway, H.; Ferrarese, C.; Hadjigeorgiou, G.; Hattori, N.; Kawakami, H.; Lambert, J. C.; Lynch, T.; Mellick, G. D.; Papapetropoulos, S.; Parsian, A.; Quattrone, A.; Riess, O.; Tan, E. K.; Van Broeckhoven, C. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. Jama 2006, 296, 661-70.
  14. Manathuga, C.; Lant, P.; Mellick, G. Imagining an interdisciplinary doctoral pedagogy. Teaching in Higher Education 2006, 11, 365-379.
  15. Elbaz, A.; Nelson, L. M.; Payami, H.; Ioannidis, J. P.; Fiske, B. K.; Annesi, G.; Carmine Belin, A.; Factor, S. A.; Ferrarese, C.; Hadjigeorgiou, G. M.; Higgins, D. S.; Kawakami, H.; Kruger, R.; Marder, K. S.; Mayeux, R. P.; Mellick, G. D.; Nutt, J. G.; Ritz, B.; Samii, A.; Tanner, C. M.; Van Broeckhoven, C.; Van Den Eeden, S. K.; Wirdefeldt, K.; Zabetian, C. P.; Dehem, M.; Montimurro, J. S.; Southwick, A.; Myers, R. M.; Trikalinos, T. A. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol 2006, 5, 917-23.
  16. Coyne, T.; Silburn, P.; Cook, R.; Silberstein, P.; Mellick, G.; Sinclair, F.; Fracchia, G.; Wasson, D.; Stanwell, P. Rapid subthalamic nucleus deep brain stimulation lead placement utilising CT/MRI fusion, microelectrode recording and test stimulation. Acta Neurochir Suppl 2006, 99, 49-50.
  17. Corder, E. H.; Mellick, G. D. Parkinson's disease in relation to pesticide exposure and nuclear encoded mitochondrial complex I gene variants. J Biomed Biotechnol 2006, 2006, 27601.
  18. Mellick, G. D.; Maraganore, D. M.; Silburn, P. A. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci Lett 2005, 375, 112-6.
  19. Kwok, J. B.; Hallupp, M.; Loy, C. T.; Chan, D. K.; Woo, J.; Mellick, G. D.; Buchanan, D. D.; Silburn, P. A.; Halliday, G. M.; Schofield, P. R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005, 58, 829-39.
  20. Gartner, C. E.; Battistutta, D.; Dunne, M. P.; Silburn, P. A.; Mellick, G. D. Test-retest repeatability of self-reported environmental exposures in Parkinson's disease cases and healthy controls. Parkinsonism Relat Disord 2005, 11, 287-95.
  21. Whitbread, A. K.; Mellick, G. D.; Silburn, P. A.; Le Couteur, D. G.; Board, P. G. Glutathione transferase Omega class polymorphisms in Parkinson disease. Neurology 2004, 62, 1910-1.
  22. Mellick, G. D.; Silburn, P. A.; Prince, J. A.; Brookes, A. J. A novel screen for nuclear mitochondrial gene associations with Parkinson's disease. J Neural Transm 2004, 111, 191-9.
  23. Mellick, G.; Price, L.; Boyle, R. Late-onset presentation of pyruvate dehydrogenase deficiency. Mov Disord 2004, 19, 727-9.
  24. Maraganore, D. M.; Lesnick, T. G.; Elbaz, A.; Chartier-Harlin, M. C.; Gasser, T.; Kruger, R.; Hattori, N.; Mellick, G. D.; Quattrone, A.; Satoh, J.; Toda, T.; Wang, J.; Ioannidis, J. P.; de Andrade, M.; Rocca, W. A. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004, 55, 512-21.
  25. Kwok, J. B.; Teber, E. T.; Loy, C.; Hallupp, M.; Nicholson, G.; Mellick, G. D.; Buchanan, D. D.; Silburn, P. A.; Schofield, P. R. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004, 55, 329-34.
  26. Deng, Y.; Newman, B.; Dunne, M. P.; Silburn, P. A.; Mellick, G. D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann Neurol 2004, 55, 897.
  27. Deng, Y.; Newman, B.; Dunne, M. P.; Silburn, P. A.; Mellick, G. D. Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson's disease. Neurosci Lett 2004, 366, 326-31.
  28. Chan, D. K.; Cordato, D.; Bui, T.; Mellick, G.; Woo, J. Comparison of environmental and genetic factors for Parkinson's disease between Chinese and Caucasians. Neuroepidemiology 2004, 23, 13-22.
  29. Blomqvist, M. E.; Silburn, P. A.; Buchanan, D. D.; Andreasen, N.; Blennow, K.; Pedersen, N. L.; Brookes, A. J.; Mellick, G. D.; Prince, J. A. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics 2004, 5, 115-9.
  30. Chan, D. K.; Mellick, G. D.; Hung, W. T.; Woo, J. Genetic and environmental risk factors and their interactions for Parkinson's disease in a Chinese population. J Clin Neurosci 2003, 10, 313-5.
  31. Le Couteur, D. G.; Muller, M.; Yang, M. C.; Mellick, G. D.; McLean, A. J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev Environ Health 2002, 17, 51-64.
  32. Chan, D. K.; Mellick, G. D.; Buchanan, D. D.; Hung, W. T.; Ng, P. W.; Woo, J.; Kay, R. Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population. J Neural Transm 2002, 109, 35-9.
  33. Buchanan, D. D.; Silburn, P. A.; Chalk, J. B.; Le Couteur, D. G.; Mellick, G. D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett 2002, 327, 91-4.
  34. Taylor, M. C.; Board, P. G.; Blackburn, A. C.; Mellick, G. D.; Le Couteur, D. G. Zeta class glutathione transferase polymorphisms and Parkinson's disease. J Neurol Neurosurg Psychiatry 2001, 70, 407.
  35. Mellick, G. D.; Buchanan, D. D.; Hattori, N.; Brookes, A. J.; Mizuno, Y.; Le Couteur, D. G.; Silburn, P. A. The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. Parkinsonism Relat Disord 2001, 7, 89-91.
  36. Taylor, M. C.; Le Couteur, D. G.; Mellick, G. D.; Board, P. G. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 2000, 107, 979-83.
  37. Mellick, G. D.; Silburn, P. A. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett 2000, 293, 127-30.
  38. Mellick, G. D.; Buchanan, D. D.; Silburn, P. A.; Chan, D. K.; Le Couteur, D. G.; Law, L. K.; Woo, J.; Pang, C. P. The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population. J Neurol 2000, 247, 52-5.
  39. McCann, S. J.; McManus, M. E.; Johnson, A. G.; Mellick, G. D.; Le Couteur, D. G.; Pond, S. M. The serotonin transporter gene and Parkinson's disease. Eur Neurol 2000, 44, 108-11.
  40. Foster, K. A.; Mellick, G. D.; Weiss, M.; Roberts, M. S. An isolated in-situ rat head perfusion model for pharmacokinetic studies. Pharm Res 2000, 17, 127-34.
  41. Chan, D. K.; Mellick, G.; Cai, H.; Wang, X. L.; Ng, P. W.; Pang, C. P.; Woo, J.; Kay, R. The alpha-synuclein gene and Parkinson disease in a Chinese population. Arch Neurol 2000, 57, 501-3.
  42. Mellick, G. D.; Roberts, M. S. Structure-hepatic disposition relationships for phenolic compounds. Toxicol Appl Pharmacol 1999, 158, 50-60.
  43. Mellick, G. D.; McCann, S. J.; Le Couter, D. G. Parkinson's disease, MAOB, and smoking. Neurology 1999, 53, 658.
  44. Mellick, G. D.; Buchanan, D. D.; McCann, S. J.; James, K. M.; Johnson, A. G.; Davis, D. R.; Liyou, N.; Chan, D.; Le Couteur, D. G. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999, 14, 219-24.
  45. Mellick, G. D.; Buchanan, D. D.; McCann, S. J.; Davis, D. R.; Le Couteur, D. G.; Chan, D.; Johnson, A. G. The ACE deletion polymorphism is not associated with Parkinson's disease. Eur Neurol 1999, 41, 103-6.
  46. Macdonald, G. A.; Tarish, J.; Whitehall, V. J.; McCann, S. J.; Mellick, G. D.; Buttenshaw, R. L.; Johnson, A. G.; Young, J.; Leggett, B. A. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol 1999, 14, 1188-91.
  47. Le Couter, D. G.; McLean, A. J.; Blackburn, A. C.; Mellick, G. D.; Board, P. G. Glutathione transferase polymorphism and Parkinson's disease. Lancet 1999, 353, 71-72.
  48. Menegon, A.; Board, P. G.; Blackburn, A. C.; Mellick, G. D.; Le Couteur, D. G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998, 352, 1344-6.
  49. Hung, D. Y.; Mellick, G. D.; Whitehead, B. D.; Roberts, M. S. The effect of protein binding on the hepatic first pass of O-acyl salicylate derivatives in the rat. J Pharm Pharmacol 1998, 50, 63-9.
  50. Hung, D. Y.; Mellick, G. D.; Masci, P. P.; Whitaker, A. N.; Whitehouse, M. W.; Roberts, M. S. Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats. J Lab Clin Med 1998, 132, 469-77.
  51. Hung, D. Y.; Mellick, G. D.; Anissimov, Y. G.; Weiss, M.; Roberts, M. S. Hepatic disposition and metabolite kinetics of a homologous series of diflunisal esters. J Pharm Sci 1998, 87, 943-51.
  52. Hung, D. Y.; Mellick, G. D.; Anissimov, Y. G.; Weiss, M.; Roberts, M. S. Hepatic structure-pharmacokinetic relationships: the hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Br J Pharmacol 1998, 124, 1475-83.
  53. Mellick, G. D.; Roberts, M. S. Impulse-response studies on tracer doses of [14C]lignocaine and its multiple metabolites in the perfused rat liver. J Pharm Pharmacol 1997, 49, 1008-18.
  54. Mellick, G. D.; Anissimov, Y. G.; Bracken, A. J.; Roberts, M. S. Metabolite mean transit times in the liver as predicted by various models of hepatic elimination. J Pharmacokinet Biopharm 1997, 25, 477-505.
  55. Hung, D. Y.; Mellick, G. D.; Prankerd, R. J.; Roberts, M. S. Synthesis, identification, characterization, stability, solubility and protein binding of ester derivatives of salicylic acid and diflunisal. International Journal of Pharmaceutics 1997, 153, 25-39.
  56. Mellick, G. D.; Roberts, M. S. The disposition of aspirin and salicylic acid in the isolated perfused rat liver: the effect of normal and retrograde flow on availability and mean transit time. J Pharm Pharmacol 1996, 48, 738-43.
  57. Mellick, G. D. Studies on the disposition of solutes in the perfused rat liver and the influence of physicochemical properties. Doctoral thesis, University of Queensland. 1996.
  58. Mellick, G. D.; Roberts, M. S. Use of a solute-container interaction to determine protein binding: application to long-chain fatty acids. J Pharm Sci 1993, 82, 1067-8.
  59. Mellick, G. D. Picolinate and catecholate models for iron (III) ferreascidin. BSc (Hons) Thesis, The University of Queensland. 1990.

Back to top

Member of Innovative Research Universities Australia